Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Myeloma cells | Image: ASH image bank
On the Path to Greater Precision in Treating Multiple Myeloma

August 18th 2025

Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will allow help researchers in multiple myeloma develop a new generation of targeted therapies, decide when treatment can be stopped, and possibly screen populations for the disease.

The model has the potential to boost early detection of MM and contribute to a paradigm shift in the treatment of MM. | Image credit: shidlovski - stock.adobe.com
Model Based on EHR Parameters Can Predict 5-Year Multiple Myeloma Risk

August 13th 2025

Joseph Mikhael, MD | Image: T-GEN
How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community

August 12th 2025

In follow-up PET/CTs, the investigators said those with complete metabolic remissions tended to have superior PFS. | Image credit: Saiful52 - stock.adobe.com
PET/CT Helps Predict Relapse in Patients With Myeloma Undergoing CAR T-Cell Therapy

August 5th 2025

Black, Hispanic, and Pacific Islander patients generally experienced worse OS compared with White patients, while Asian patients had similar outcomes. | Image credit: Colored Lights - stock.adobe.com
Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

July 28th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
August 19th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 19th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
August 19th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
August 19th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 19th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Robert Rifkin, MD, FACP
January 13th 2022

Dr Robert Rifkin on Future Investigations Into Multiple Myeloma

Gianna Melillo
Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines multiple myeloma research he hopes to see in the next 5 years.
data set
January 11th 2022

Interview: Real-World Data Show Daratumumab 1L Improves OS in Some Patients With MM

Mary Caffrey
For patients with multiple myeloma (MM) who are not eligible for transplant, should novel treatments be used right away? Or should clinicians save the best potential therapies for relapses, which are inevitable with this disease?
Robert Rifkin, MD, FACP
January 7th 2022

Dr Robert Rifkin Describes Research on Triple-Class Refractory MM Patients

Gianna Melillo
Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses his research using real-world data from patients with triple-class refractory multiple myeloma.
old man
January 3rd 2022

Analysis Identifies Potential Biomarker of Frailty in Multiple Myeloma

Gianna Melillo
Neutrophil to lymphocyte ratio may indicate the presence of frailty among older adults with multiple myeloma.
Robert Rifkin, MD, FACP
December 31st 2021

Dr Robert Rifkin Discusses Treatment Resistance in Multiple Myeloma

Gianna Melillo
Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines the importance of studying treatment resistant patients with multiple myeloma.
Expert on Multiple Myeloma
December 23rd 2021

Upcoming Post-Conference Perspectives: ASH 2021

Rafael Fonseca, MD
Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.
scientists in lab
December 22nd 2021

Phase 1/2 Trial Results Underscore Teclistamab’s Efficacy in RRMM

Gianna Melillo
Updated results of the MajesTEC -1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate of 62% among heavily pretreated patients with multiple myeloma.
Robert Rifkin, MD, FACP
December 20th 2021

Dr Robert Rifkin Explains the Importance of Real-world Data in MM Patient Populations

Gianna Melillo
Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, describes his research on real-world treatment patterns among patients with triple-class refractory multiple myeloma.
iStopMM: Investigators From Iceland Report First Results of Population-Based Screening for Multiple Myeloma
December 18th 2021

iStopMM: Investigators From Iceland Report First Results of Population-Based Screening for Multiple Myeloma

Mary Caffrey
Five years ago, investigators in Iceland sought to evaluate what would happen if screening for MGUS were widely available—and whether it would improve overall survival.
Picture of abnormal cells in bone marrow
December 15th 2021

Sub-Q Isatuximab Combo Offers Safety, Efficacy Profile Comparable With Phase 3 Results in IV Formulation

Mary Caffrey
Subcutaneous (sub-Q) administration of isatuximab plus pomalidomide may provide survival advantages for patients with relapsed and refractory multiple myeloma, making it another treatment option for this patient group.
Anne Quinn Young, MPH, brand president, MMRF
December 8th 2021

The MMRF: Understanding and Sharing the Genomic Landscape of Multiple Myeloma

Maggie L. Shaw
The Effect of Evolving Treatment Options on the Management of Multiple Myeloma
December 8th 2021

The Effect of Evolving Treatment Options on the Management of Multiple Myeloma

blue cross
December 6th 2021

Postmarketing Surveillance Study Finds Ixazomib Safety Profile Acceptable in RRMM

Gianna Melillo
Real-world evidence from Japan found ixazomib has an acceptable safety profile in patients with relapsed/refractory multiple myeloma (RRMS).
pills in box
December 1st 2021

Real-world Evidence Details Use of Ixazomib as Maintenance Therapy for MM

Gianna Melillo
Results of a retrospective study conducted in China assessed the safety and efficacy of ixazomib for multiple myeloma.
elderly woman
April 4th 2021

Older Patients With MM Can Forgo Steroids in Treatment and See Similar Outcomes

Laura Joszt, MA
The combination of lenalidomide with steroid dexamethasone is standard of care in multiple myeloma (MM), but new research shows older patients can be spared the steroids.
red blood cells
March 25th 2021

Trial Analyzes Efficacy of Tailoring MM Treatment to MRD Response

Gianna Melillo
Twice weekly high doses of carfilzomib in combination with lenalidomide and dexamethasone was tolerable and effective among patients with newly diagnosed multiple myeloma.
Optimizing the Use of MRD Testing in Multiple Myeloma
March 18th 2021

Optimizing the Use of MRD Testing in Multiple Myeloma

Laura Joszt, MA
Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing.
Highlighting Resiliency During Multiple Myeloma Awareness Month 2021
March 13th 2021

Highlighting Resiliency During Multiple Myeloma Awareness Month 2021

AJMC Staff
Multiple myeloma is not easily diagnosed, and its early symptoms may be confused for another condition.
CAR T Therapy Induces Response in Majority of Patients With Relapsed Multiple Myeloma
March 10th 2021

CAR T Therapy Induces Response in Majority of Patients With Relapsed Multiple Myeloma

Laura Joszt, MA
Idecabtagene vicleucel induced progression-free survival up to 20 months and a complete response in one-third of patients with multiple myeloma who had relapsed multiple times and had received at least 3 previous lines of treatment.
<1
...
8910111213>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo